Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
96.95
-2.05 (-2.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Short Sellers Are Betting Against Novavax (NVAX) Stock
October 04, 2023
Shorts are betting no one will want Novavax's Covid-19 vaccine, but the pandemic is not yet over, and NVAX stock is cheap.
Via
InvestorPlace
Exposures
COVID-19
Novavax Surges After FDA Signs Off On Its Updated Covid Shot, Joining Pfizer, Moderna
October 03, 2023
The company can now join Pfizer and Moderna in launching an updated booster in the U.S.
Via
Investor's Business Daily
Exposures
COVID-19
Product Safety
Novavax Stock Soars On FDA Clearance For Updated Covid-19 Shot: What's Going On?
October 03, 2023
Novavax Inc (NASDAQ: NVAX) shares are surging Tuesday afternoon after the U.S.
Via
Benzinga
Exposures
COVID-19
Product Safety
Nobel Prize Honors Scientists Behind mRNA Vaccines Against Covid-19
October 02, 2023
Discover the remarkable journey of Nobel Prize laureates Kariko and Weissman, who transformed medicine with mRNA vaccines, and the financial impact on Moderna and Pfizer stocks.
Via
Benzinga
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street
October 01, 2023
Analysts like these stocks for very good reasons.
Via
The Motley Fool
BioNTech Unusual Options Activity For August 30
August 30, 2023
Via
Benzinga
Expert Ratings for BioNTech
August 28, 2023
Via
Benzinga
Why Pfizer and BioNTech Stocks Zoomed Higher Today
September 29, 2023
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.
Via
The Motley Fool
Exposures
COVID-19
Why CureVac Stock Plunged Today
September 29, 2023
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
Via
The Motley Fool
Topics
Lawsuit
Exposures
Financial
Legal
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
September 27, 2023
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...
Via
Benzinga
DNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With Pfizer
September 27, 2023
The deal keeps Ginkgo alive, but its business model of becoming the "Apple Store of Biotech" remains unproven. DNA stock jumped overnight.
Via
InvestorPlace
Updated Covid Vaccine US Rollout Hit by Insurance Coverage Delays - What It Means?
September 20, 2023
As the U.S.
Via
Benzinga
Exposures
COVID-19
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
September 20, 2023
All three companies should benefit from increased COVID-19 booster sales.
Via
The Motley Fool
Exposures
COVID-19
10 Health Care Stocks Whale Activity In Today's Session
September 18, 2023
Via
Benzinga
More Than Half Of Americans Want New COVID-19 Booster, But Ron DeSantis Will Fight Virus With His Charisma Alone
September 15, 2023
New COVID-19 boosters have been approved by the U.S. FDA in the fight against new variants. A new survey showed how likely people are to get new boosters and if they will have their children get...
Via
Benzinga
Exposures
COVID-19
Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
September 14, 2023
Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now.
Via
InvestorPlace
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
September 13, 2023
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite.
Via
Investor's Business Daily
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
September 12, 2023
Benzinga
Via
Benzinga
Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits
September 11, 2023
The U.S.
Via
Benzinga
Exposures
COVID-19
Product Safety
Non-Disappearing COVID Creates Another Chapter For The Pharmaceutical Industry
September 06, 2023
On Tuesday, UK regulators joined their US and European peers in approving an updated COVID-19 vaccine by Pfizer Inc (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) that targets only the...
Via
Benzinga
Exposures
COVID-19
Here's How Moderna's Updated Covid Shot Stacks Up Against Highly Mutated 'Pirola' Variant
September 06, 2023
Pirola has about 30 mutations compared with previous omicron versions of the virus.
Via
Investor's Business Daily
Exposures
COVID-19
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
September 05, 2023
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'...
Via
Benzinga
Exposures
COVID-19
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
September 02, 2023
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet...
Via
Talk Markets
Jeff Bezos Vs. Elon Musk Space Contract Lawsuit, Novo Nordisk's Famed Drug Ozempic Could Be Next Contender For Medicare Negotiations, Tesla Rival XPeng's August Deliveries Zooms 43%: Today's Top Stories
September 01, 2023
Tech Crunch
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Europe Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination Campaigns
September 01, 2023
The European Commission has approved Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech SE (NASDAQ:
Via
Benzinga
Exposures
COVID-19
Why Novavax Stock Was So Healthy on Monday
August 28, 2023
As the coronavirus threat rises, so too does the vaccine maker's value to investors.
Via
The Motley Fool
Exposures
COVID-19
Why BioNTech Shares Are Rising During Monday's Session
August 28, 2023
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by some 2.25% to $120.26 Monday. The stock is gaining today amid rising COVID-19 cases in the U.S.
Via
Benzinga
Exposures
COVID-19
5 Value Stocks To Watch In The Healthcare Sector
August 28, 2023
Via
Benzinga
COVID Is Making a Comeback: Should You Buy These 2 Stocks?
August 27, 2023
Can these companies keep up their recent momentum?
Via
The Motley Fool
Exposures
COVID-19
Novavax (NVAX) Stock Is Getting Ready to Rally Again
August 22, 2023
Novavax only has an Emergency Use Authorization and faces a struggle to get paid for its protein-based Covid shot.
Via
InvestorPlace
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.